Cancer Research

Potential new therapeutic targets to treat melanoma

Penn Medicine research shows that a relative lack of DOPA, and not simply susceptibility to sun damage, helps explain why melanoma is much more common in people with light skin tones.

Alex Gardner



Media Contact


Experts



In the News


The Scientist

Armored CAR T cells break through immune suppression in solid tumors

A study by Joseph Fraietta of the Perelman School of Medicine and colleagues found a way to “armor” CAR T cells, enabling them to get past immunosuppressors in prostate cancer.

FULL STORY →



Forbes

University of Pennsylvania receives $55 million gift to study, treat hereditary cancers

The $55 million gift from alumni Mindy and Jon Gray will be used to establish the Basser Cancer Interception Institute, featuring a statement from President Liz Magill.

FULL STORY →



Bloomberg

Blackstone’s Gray gives UPenn $55 million for cancer prevention

Alums Mindy and Jon Gray are funding the Basser Institute for Cancer Interception to focus on early detection and prevention of breast, ovarian, pancreatic, and prostate cancers.

FULL STORY →



Philadelphia Inquirer

$55 million gift to Penn is aimed at stopping breast cancer before it starts

Mindy and Jon Gray’s new Basser Institute is a spinoff of their previously funded Basser Center for BRCA, named for Mindy’s late sister Faith Basser and led by Susan Domchek of the Perelman School of Medicine.

FULL STORY →



Science

Cell-killing cancer therapy shows promise for a devastating autoimmune disorder

Aimee Payne of the Perelman School of Medicine says that the University of Erlangen-Nürnberg’s new CAR-T therapy lupus research represents a landmark study in the treatment of autoimmunity.

FULL STORY →



Philadelphia Business Journal

Penn spinout Capstan Therapeutics launches with $165M and an all-star lineup of founders

Capstan Therapeutics, a Penn spinout whose founders include Carl June, Bruce Levine, and Drew Weissman of the Perelman School of Medicine, has launched with $165 million raised to develop a new type of CAR therapy that incorporates mRNA.

FULL STORY →